Vor Biopharma (NYSE:VOR) Receives “Outperform” Rating from Oppenheimer
Oppenheimer restated their outperform rating on shares of Vor Biopharma (NYSE:VOR – Free Report) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a $8.00 target price on the stock. A number of other research analysts have also recently issued reports on VOR. Wedbush reiterated an “outperform” rating and […]
Oppenheimer restated their outperform rating on shares of Vor Biopharma (NYSE:VOR – Free Report) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a $8.00 target price on the stock. A number of other research analysts have also recently issued reports on VOR. Wedbush reiterated an “outperform” rating and […]
